NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Yes. Agree with that. They need to demonstrate that the handful of patients with IDH mutation were spread across both arms at approx the same percentage. And they probably were, because of the matching age stratification across arms.
And you would hope that treatment / control OS delta would be broadly the same for the 5% mutated as it is for the 95% wildtype.

(I could see a narky regulator suggesting that because of the small mutated numbers, the treatment effect has only been properly demonstrated on wild type. Which could possibly mean approval for the 95% and not the 5%. But unlikely.)